Section Arrow
Quote
PTHS.NYSE-M
- Pelthos Therapeutics Inc
Quotes are at least 15-min delayed:2025/08/17 19:02 EDT
Regular Hours
Last
 20.96
+2 (+10.55%)
Day High 
21.49 
Prev. Close
18.96 
1-M High
22.695 
Volume 
25.23K 
Bid
19.7
Ask
21
Day Low
18.95 
Open
18.95 
1-M Low
16.5 
Market Cap 
12.30M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 19.7 
20-SMA 20.53 
50-SMA 17.34 
52-W High 54.29 
52-W Low 4.5 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-12.00/-0.70
Enterprise Value
12.30M
Balance Sheet
Book Value Per Share
-6.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PGENPrecigen2.94+1.09+58.92%-- 
ADAPAdaptimmune Therapeutics plc0.0595-0.0134-18.38%-- 
IOBTIO Biotech2.16+0.88+68.75%-- 
TNFATNF Pharmaceuticals Inc.0.101-0.0013-1.27%-- 
LPTXLeap Therapeutics0.2681+0.0245+10.06%-- 
Quotes are at least 15-min delayed：2025/08/17 19:02 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.